Abstract
We appreciate the comments of Anand with respect to the nephrotoxic potential of ciprofloxacin. In our first trial of outpatient antibiotic therapy in low-risk, neutropenic cancer patients, we used a higher-than-usual dose of ciprofloxacin (750 mg orally every 8 hours), based on data indicating reduced absorption of orally administered ciprofloxacin after antineoplastic chemotherapy. 1 The study by Ljungberg and Nilsson-Ehle, 2 demonstrating increased oral bioavailability and reduced renal clearance of ciprofloxacin in elderly patients is of interest, and may in part explain our experience in elderly oncologic patients. Although acute renal failure has been associated with ciprofloxacin administered at much lower doses (200 mg every 12 hours), in our second study of outpatient antibiotic therapy of low-risk neutropenic patients we have reduced the dose of ciprofloxacin to 500 mg orally every 8 hours. Also, we have substituted amoxicillin/clavulanate for clindamycin in the oral regimen of our second trial, although, as
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
